We are excited to welcome the newly elected members of the BIA Board of Directors, who will bring fresh insights and expertise to help drive our mission forward. Nick Gardiner, Chief Operating Officer and the Company Secretary, shares his perspective on the importance of these appointments and the unique value each new Director brings to the BIA.

As the Company Secretary of the BioIndustry Association (BIA), I am pleased to announce the members who have been elected to our Board of Directors and will begin their terms in January 2026. BIA members elect or re-elect five Board Directors from the membership, four from the Corporate membership category and one from our Associate/Network companies.

The new Board Directors were voted for by the BIA’s membership in the weeks leading up to the AGM, which was held on Tuesday, 21 October 2025 and attended by over 40 member companies. All present approved the appointment of the Directors and all of the other proposed resolutions.

The following members will join the BIA Board from 1 January 2026, for a three-year term, adding to the considerable industry expertise that the Association can draw upon.

The following have been newly elected to the BIA Board:

The following have been re-elected to the Board:

Dan Mahony, the Chair of the BIA, also announced that Olivia Cavlan of LifeArc and Robert Tansley of Cambridge Innovation Capital have decided to step down at the end of December. Nerida Scott resigned as a Board member in the summer.

This was also Dan’s final AGM as our Chair, and Shaun Grady, Chair of AstraZeneca UK, will take over from January 2026. He paid tribute to Dan and provided this comment earlier in the year: